EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models

Yanru Guo, Saidu Kamara, Jing Zhang, He Wen, Maolin Zheng, Ying Liu, Luqi Zhou, Jun Chen, Shanli Zhu, Lifang Zhang

Frontiers in Cellular and Infection Microbiology · 2023

DOI: 10.3389/fcimb.2022.1078504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2023. Verfasst von Yanru Guo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical Universi…. Hauptthemen laut MEDLINE: Epstein-Barr Virus Infections, Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nasopharyngeal carcinoma (NPC), is an Epstein-Barr virus (EBV) associated malignancy most common in Southern China and Southeast Asia. In southern China, it is one of the major causes of cancer-related death. Despite improvement in radiotherapy and chemotherapy techniques, locoregional recurrence and distant metastasis remains the major causes for failure of treatment in NPC patients. Therefore, finding new specific drug targets for treatment interventions are urgently needed. Here, we report three potential Z LMP1-C affibody molecules (Z LMP1-C 15, Z LMP1-C 114 and Z LMP1-C 277) that showed specific binding interactions for recombinant and native EBV LMP1 as determined by epitope mapping, co-localization and co-immunoprecipitation assays. The Z LMP1-C affibody molecules exhibited high antitumor effects on EBV-positive NPC cell lines and displayed minimal cytotoxicity towards EBV-negative NPC cell line. Moreover, Z LMP1-C 277 showed higher antitumor efficacy than Z LMP1-C 15 and Z LMP1-C 114 affibody molecules. The ability of Z LMP1-C 277 decrease the phosphorylation levels of up-stream activator phospho-Raf-1 (Ser338) , phospho-MEK1/2 (Ser217/Ser221) , phospho-ERK1/2 (Thr202/Thr204) , thereby leading to downstream suppression of phospho-p90RSK (Ser380) and transcription factor c-Fos. Importantly, tumor growth was reduced in tumor-bearing mice treated with Z LMP1-C 277 and caused no apparent toxicity. Taken together, our findings provide evidence that Z LMP1-C 277 as a promising therapeutic agent in EBV-associated NPC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epstein-Barr Virus InfectionsNasopharyngeal CarcinomaNasopharyngeal NeoplasmsAnimalsHumansMiceCell Line, TumorCell ProliferationHerpesvirus 4, HumanMAP Kinase Signaling SystemMitogen-Activated Protein Kinase KinasesNeoplasm Recurrence, LocalRibosomal Protein S6 Kinases, 90-kDaXenograft Model Antitumor Assays

Stichwörter der Autor:innen

EBVLMP1affibody moleculesnasopharyngeal carcinomatargeted therapy

Substanzen

Mitogen-Activated Protein Kinase KinasesRibosomal Protein S6 Kinases, 90-kDa

Autor:innen und Institutionen

  • Institute of Molecular Virology and Immunology, Department of Microbiology and Immunology, School of Basic Medical Sciences, Wenzhou Medical University, Wenzhou, Zhejiang, China.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Guo, Y., Kamara, S., Zhang, J., Wen, H., Zheng, M., Liu, Y., Zhou, L., Chen, J., Zhu, S., & Zhang, L. (2023). EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2022.1078504

Vancouver

Guo Y, Kamara S, Zhang J, Wen H, Zheng M, Liu Y, et al. EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models. Frontiers in Cellular and Infection Microbiology. 2023. doi:10.3389/fcimb.2022.1078504

BibTeX
@article{Guo2023,
  author = {Guo, Yanru and Kamara, Saidu and Zhang, Jing and Wen, He and Zheng, Maolin and Liu, Ying and Zhou, Luqi and Chen, Jun and Zhu, Shanli and Zhang, Lifang},
  title = {EBV LMP1-C terminal binding affibody molecule downregulates MEK/ERK/p90RSK pathway and inhibits the proliferation of nasopharyngeal carcinoma cells in mouse tumor xenograft models},
  journal = {Frontiers in Cellular and Infection Microbiology},
  year = {2023},
  doi = {10.3389/fcimb.2022.1078504}
}
Kostenlos starten →